

## HR 5729

Adding Ebola to the FDA Priority Review Voucher Program Act

**Congress:** 113 (2013–2015, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Nov 18, 2014

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Nov 21, 2014)

**Official Text:** <https://www.congress.gov/bill/113th-congress/house-bill/5729>

### Sponsor

**Name:** Rep. Blackburn, Marsha [R-TN-7]

**Party:** Republican • **State:** TN • **Chamber:** Senate

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Nov 18, 2014
Rep. Fleischmann, Charles J. "Chuck" [R-TN-3]	R · TN		Nov 18, 2014
Rep. Green, Gene [D-TX-29]	D · TX		Nov 18, 2014
Rep. McCaul, Michael T. [R-TX-10]	R · TX		Nov 18, 2014

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 21, 2014

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
113 S 2917	Identical bill	<b>Dec 16, 2014:</b> Became Public Law No: 113-233.

Adding Ebola to the FDA Priority Review Voucher Program Act - Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.)

Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS).

Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times. Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.

### **Actions Timeline**

---

- **Nov 21, 2014:** Referred to the Subcommittee on Health.
- **Nov 18, 2014:** Introduced in House
- **Nov 18, 2014:** Referred to the House Committee on Energy and Commerce.